N4 Pharma plc (N4P)
Market Closed
10 Aug, 15:30
LSE 
XFRA Primary LSE 0. 70
GBX +0.03
+3.9347%
2.17M Market Cap
- P/E Ratio
- Div Yield
190,988 Volume
- Eps
0.67 GBX
Previous Close Want to track N4P and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
N4P closed Monday higher at 0.7 GBX, an increase of 3.9347% from Friday's close, completing a monthly increase of 7.6923% or 0.05 GBX. Over the past 12 months, N4P stock gained 33.3333%.
N4P is not paying dividends to its shareholders.
The last earnings report, released on Sep 22, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
N4 Pharma plc has completed 2 stock splits, with the recent split occurring on May 03, 2017.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
N4 Pharma plc (N4P) FAQ
What is the stock price today?
The current price is 0.70 GBX.
On which exchange is it traded?
N4 Pharma plc is listed on LSE.
What is its stock symbol?
The ticker symbol is N4P.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 2.17M.
Has N4 Pharma plc ever had a stock split?
N4 Pharma plc had 2 splits and the recent split was on May 03, 2017.
N4 Pharma plc Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Dr. David Horn Solomon M.D. CEO | LSE Exchange | GB00BYW8QM32 ISIN |
| United Kingdom Country | 4 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
N4 Pharma Plc is a distinguished specialist pharmaceutical company operating out of London, United Kingdom. Since its incorporation in 1979, the company has been at the forefront of developing innovative silica nanoparticle delivery systems. These advanced systems are designed to serve the pharmaceutical and biotechnology sectors within the UK, offering new possibilities in the delivery of therapeutics. N4 Pharma Plc is dedicated to revolutionizing the healthcare industry by providing cutting-edge solutions that enhance the efficacy and delivery of vaccines and cancer treatments.
Products and Services
- Nuvec - A groundbreaking non-viral adjuvant delivery system primarily aimed at enhancing the delivery of vaccines and cancer treatments. Nuvec is an innovative solution developed by N4 Pharma Plc to address the limitations of current delivery systems in the biopharmaceutical industry. By employing silica nanoparticles, Nuvec significantly improves the stability and efficiency of therapeutic delivery, ultimately leading to more effective treatment outcomes. It stands at the forefront of N4 Pharma's efforts to contribute to the advancement of medical science and patient care.
Contact Information
Address: 2 Portman Street
Phone: 44 20 4610 0714
Website: https://www.thaliatx.com
